Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

1H25 Result: Don’t dream it’s over

Lovisa
3:27pm
February 24, 2025
The pace of store rollout has started to accelerate after a period of consolidation, notably in the US over the past two years. We believe Lovisa is poised to hit the landmark of 1,000 stores before the end of the current half, possibly by the time the outgoing CEO Victor Herrero hands over the reins on 31 May. This underscores what we see as the most important element of the Lovisa investment case: the business has a subscale presence in almost every one of the 50 markets in which it operates and significant long-term growth potential in each. We believe the platform for long-term growth is getting stronger all the time. We reiterate our ADD rating. Our target price moves from $36 to $35. LFL sales in 1H25 were less than we had expected at +0.1% (MorgansF: +1.0%) but accelerated to +3.7% in the first 7 weeks of 2H25. This flowed through to 3% lower EBIT than forecast, despite gross margins exceeding our estimate by 90 bps. Lead coverage of Lovisa transfers to Emily Porter with this note.

Trading opportunity emerges with share price fall

Polynovo
3:27pm
February 24, 2025
PNV posted its 1H25 result which was in line with expectations. However, the share price fell sharply (down 8%) which we found surprising and believe has created a buying opportunity. Our forecast growth of 29% for FY25 appears achievable driven by regional expansion and additional indications. We have made no changes to forecasts or TP. Add recommendation maintained.

It’s still tough out there

Reece
3:27pm
February 24, 2025
REH’s 1H25 result was slightly weaker than expected with the housing outlook in both ANZ and the US remaining soft. Key positive: Balance sheet remains healthy with ND/EBITDA (ex-leases) at 0.8x, leaving capacity for ongoing growth investments that will benefit the business over the long term. Key negatives: Volumes and margins were lower in both ANZ and the US; Increased competition has led to market share loss in the US; Cost inflation remains a headwind. We decrease FY25-27F EBITDA by between 2-3%. Our target price falls to $18.70 (from $19.95) and with a 12-month forecast TSR of -1%, we upgrade our rating to Hold (from Reduce). While we continue to see REH as a good business with a strong culture and long track record of growth, the outlook for housing in the near-term remains uncertain despite a likely peak in central bank interest rates in both Australia and the US. REH will also need to respond to aggressive competition in the US, which also adds to the uncertainty on the earnings outlook.

All weather steel cycle performance, with yield

Stanmore Resources
3:27pm
February 24, 2025
Key CY24 financials beat our expectations driven by better realisations/ revenues. The US 6.7c dividend was a positive surprise, helped by a robust balance sheet and a material step down in 2025 capex as internal investment completes. CY25 guidance was materially better than our conservative expectations. SMR trades at ~0.65x P/NPV reflecting depressed investor interest and opacity in the global steel outlook. With a robust balance sheet, and dividends through the cycle, we think SMR offers a compelling option over steel market upside in time for patient investors.

Will organisational reshuffles

Ramsay Health Care
3:27pm
February 24, 2025
Since taking over the reins last Dec, CEO Natalie Davis has started running a ruler over operations, flagging senior leadership changes, updating the operational structure and writing down goodwill related to Elysium mental health business in the UK. Preliminary 1HFY25 results have also been released, which sees underlying operating income decline 1-3% on pcp, and management no longer expecting NPAT growth in FY25. At this early stage, it is difficult to assess if adjustments in operational strategy will have the desired impact, so we continue to remain cautious. We adjust FY25-27 earnings lower, mainly in out years, with our price target decreasing to A$37.74. Hold. CFO Martyn Roberts and Australia CEO Carmel Monaghan will be exiting stage left, with Mr Roberts resigning to “pursue other opportunities” and Ms Monaghan retiring mid-2025. Both will remain with the company during a transition phase. An updated operational structure, which aims to “strengthen the group’s focus on its core Australian hospital business, while building the capabilities necessary to drive transformation and shareholder value”, is slated to be implemented by mid-25 with key changes including: RHC will take a A$291m post-tax goodwill impairment of Elysium, driven by continued occupancy challenges in mental health rehabilitation and neurological services, as well as a slower than planned ramp up in occupancy at new site, partially offset by the increase in valuation for UK Hospitals driven by an improved tariff outlook in 2004/05 and public/private partnership momentum. In an attempt to improve Elysium’s performance, a COO commended in Jan-25, targeting “operational rigour” with a “focus on financial outcomes”. In addition, consultants have been hired to “identify initiatives to improve profitability”. A A$64.5m tax liability provision release for Ramsay Santé will also be taken, as the time period to hold the provision has lapsed.

NEU adds another two zombie designations

Neuren Pharmaceuticals
3:27pm
February 24, 2025
NEU has announced the granting of FDA’s Rare Pediatric Disease Designation (RPD) for both Pitt Hopkins (PH) and Angelman Syndrome (AS), both neurological disorders which emerge in early childhood and currently have no approved treatments. These designations allow companies to apply for various incentives, including the highly-prized Priority Review Voucher (PRV) which awards RPD participants a voucher which can be used to accelerate the FDA’s review process, or can opt to on-sell to another drug developer to use. However, there remains uncertainty under current legislation where the PRV program was active up until September 2024 but has not since been reauthorised. The sunsetting of incentives currently only allows the awarding of the vouchers for approved designations up until late 2026, but seemingly not the qualifying tickets to entry which it continues to award. Given the time it takes to run Ph3 pivotal trials along with the NDA submission process, the designations are effectively zombie designations with no material benefit unless US congress reauthorise the program. A bill introduced in December 2024 (with bipartisan support) which would have extended the sunset date for another 4+ years ran into political challenges and ultimately stripped back many provisions which included the PRV extension. We note that congress has since passed several of the bills originally stripped out of the continuing resolutions, which gives some degree of hope for the program in the near-term. However, from our searches we cannot find any current commentary from the FDA or heard of this program being on the ticket for discussion at the congressional level at this stage.

1H25 earnings: From holding the ball to tightening the reins

Tabcorp Holdings
3:27pm
February 24, 2025
TAH’s 1H25 result was its most encouraging update for some time prompting a positive share price reaction on the day. The appointment of Gill McLachlan as CEO is a key catalyst for driving change, as reflected in his first interim result. Despite softer turnover, total domestic wagering revenue (pre-VRI interest) rose 1%, supported by strong cash performance and resilient digital yields. Encouragingly, FY25 OpEx savings guidance increased from $20m to $30m (MorgansF: $693m) while CapEx and D&A guidance were also revised downwards. Following the result, we have raised our earnings forecasts by 3.2% in FY25 and 1.4% in FY26. Our key takeaway from the investor call is a notable shift in sentiment compared to the previous year. While near-term wagering conditions may appear choppy, we see long-term potential, supported by a series of specialised hires aimed at maximising value from TAH's existing asset base. We upgrade TAH to an Add recommendation and increase our price target to $0.75.

Cooler Runnings

Lindsay Australia
3:27pm
February 23, 2025
LAU’s 1H25 result was much weaker than expected as softer trading conditions and increased competition impacted LAU’s transport segment. Group EBITDA (pre AASB16) of A$47.3m was down -9.2% yoy, -7% lower than MorgF $50.8m. Underlying NPAT also fell -20% yoy to $15.8m also short of MorgF/ Consensus. Management commentary reflects expectations for operating conditions to remain challenging into 2H25. Given this near-term outlook and uncertainty surrounding the recovery in broader conditions we reduce FY25-27F EBITDA by -15%. We move to a Hold rating with a revised target of $0.80ps (from $1.15ps).

1H25 earnings: Upside beyond jackpot cycles

Jumbo Interactive
3:27pm
February 23, 2025
JIN delivered a resilient result despite a weaker jackpotting period in the first half. Looking ahead, JIN will be comping its strongest second half to date, though margins should benefit from effective cost management and incremental upside from Daily Winners. We remain comfortable sitting below consensus for FY26, given uncertainties around draws and recovery in Managed Services. Despite this, we see limited downside (<10x FY25-26F EV/EBITDA), supported by a strong net cash position. We see upside to guided Managed Services margins, driven by contract mix and FX benefits. We maintain our Add recommendation, with our PT reduced to $13.60 (previously $14.60).

Lets taco’bout those comps

Guzman y Gomez
3:27pm
February 23, 2025
Whilst GYG’s 1H25 result didn’t deliver a much anticipated beat and consensus earnings upgrade, it was nonetheless a strong half of execution and growth. Importantly, comp sales growth continues to accelerate into the 2H25 and GYG now expects to exceed its prospectus forecasts (consensus was already above). Following share price weakness, we upgrade to ADD.

News & Insights

The US economy is growing strongly at 2.34% in Q2 2025 but is expected to slow to 1.4% in 2025, with falling interest rates and a weaker US dollar likely to boost commodity prices, benefiting Australian markets. Michael Knox discusses.

We think the US economy is currently experiencing solid growth, with data from the Chicago Fed  National Activity Index indicating an annual growth rate of just above  2%. This aligns with projections from other parts of the Federal Reserve System, such as the New York Fed. The New York Fed’s weekly Nowcast, updated every Friday, estimates that for the second quarter of 2025, the US economy is growing at an annualised rate of 2.34%, surpassing the 2% mark. This robust growth is consistent with our model’s view that the US economy is now performing strongly. However, we anticipate a slowdown in the second half of 2025.

On 18 June the Fed released its Summary of Economic Projections  with the Federal Reserve’s  forecasting US GDP growth to drop to 1.4% in 2025, down from their March estimate of 1.7%. Looking further ahead, growth is expected to pick up slightly to 1.6% in 2026 and 1.8% in 2027, aligning with the long-term trend growth rate of around 1.8%. We believe this recovery trend could be even  higher,  driven by reduced regulation under the second Trump administration and aggressive tax write-offs for companies building factories in the US, allowing 100% write-offs for equipment and buildings in the first year. This policy should foster stronger systemic growth.

Economic Projections of the Federal Reserve

The Fed expects that as the economy slows,  unemployment is projected to rise to 4.5% from the current level of 4.2%. Inflation, measured by the Consumer Price Index (CPI), is running at 3.5% this year, approximately 50 basis points higher than the Personal Consumption Expenditures (PCE) index of 3.0%, with 1.6% of this  inflation  attributed to tariffs. The Fed expects PCE Inflation  to ease to 2.4% in 2026 and 2.1% in 2027. The Federal Reserve anticipates cutting the effective  federal funds rate, currently at 433 basis points (according to the New York Fed), by 50 basis points by the end of 2025, followed by an additional 25 basis points in each of the next two years. This aligns with our own Fed Funds rate  model’s current equilibrium federal funds rate of  3.85% . The Fed Outlook  supports our scenario of a slowing US economy and rate cuts in the second half of 2025 and beyond. A falling US dollar is then expected to exert upward pressure on commodity prices, benefiting Australian Equity markets.

Taking questions during the Press Conference after releasing the Fed statement  ,Federal Reserve Chair Jay Powell,   addressed the certainty and uncertainty surrounding the inflationary effects of tariffs. Initially, at the start of 2025, the inflationary impact of tariff policies was unclear, but three months of favourable inflation data have provided this clarity, indicating that the inflationary effects are less severe than anticipated. Powell noted that the Feds own uncertainty on the inflationary effects of  tariffs  peaked in April 2025, and the Federal Reserve now has a clearer understanding that  the inflation effects, are lower than initially expected.

The Fed view  supports our own scenario of a slowing US economy in the second half of 2025, allowing for Fed rate cuts  . This in turn should then lead to  a falling US dollar, which we in turn  expect to drive rising commodity prices.

Read more
The Your Wealth publication is our half yearly scrutiny into current affairs for wealth management. Our latest Issue 29 is out now.

The second half of 2025 will be an interesting time for everyone. Geopolitical uncertainty prevails. How will all of this impact the Australian investor and in particular, their wealth and retirement savings? Whether you are an accumulator, saving for short- and long-term goals, or a retiree, hoping for a comfortable retirement, the ability to manage this uncertainty will be key.

When we published the previous Your Wealth – First Half 2025, the Division 296 Bill (Div296) was also facing uncertainty. The Bill was eventually blocked in the Senate prior to the Federal Election. The Labor Party succeeded in winning so it’s Ground Hog Day for Div296. The Government doesn’t have the numbers in the Senate to pass the Bill without support from other parties. The Greens are the likely negotiating party but will undoubtably have their own agenda. Regardless, there is a high probability this legislation will be passed once Parliament resumes.

Our message to our clients is to wait until we know more details and to not act in haste.

In addition to our Feature Article which provides further insights on Div296, this edition also Spotlights the Aged Care changes due this year, with the start date pushed back to 1 November.

We hope readers enjoy this edition of Your Wealth.


Morgans clients receive exclusive insights such as access to our latest Your Wealth publication. Contact us today to begin your journey with Morgans.

      
Contact us
      
Read more
Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more